Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

DEVOTE trial: long-acting insulin results

bs_subtitle

Peter Sayer, Alison Bloomer, and Eve Batt report from the 77th annual Scientific Sessions of the American Diabetes Association (ADA). The results demonstrated a significantly lower rate of severe hypoglycaemia with insulin degludec treatment compared with insulin glargine U100. These findings, which are the first to specifically examine the CV impact of insulin degludec, provide further evidence to support its safety profile and are in line with previous studies. Dr Ponnusamy Saravanan, Associate Clinical Professor and Honorary Consultant Physician in Diabetes, Endocrinology & Metabolism, University of Warwick, commented: “There are four million people living with type 2 diabetes in the UK. Given the

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy